Paramount Global (PARA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Jaime Morris - EVP - IRChris McCarthy - CEO and President & CEO - SHOWTIME & MTV Entertainment StudiosGeorge Cheeks - CEO and President & CEO - CBSBrian Robbins - CEO and President & CEO - Paramount Pictures and NickelodeonNaveen Chopra - Executive VP & CFORic Prentiss - Managing DirectorKutgun Maral - Director Conference Call Participants Steven Cahall - Managing Director, Senior Analyst - Media, Advertising & Cable ...

Financial Data and Key Metrics Changes - Onto Innovation achieved a record revenue of $267 million for the first quarter, representing a 17% increase year-over-year and a 28% increase in EPS compared to the prior year [4][11] - The company reported an operating cash flow of $92 million, which is 35% of revenue, and free cash flow of $84 million, or 31% of revenue, converting 100% of operating income into cash [11][13] - Gross margin for the first quarter was 55%, slightly above the guidance range of 54% to 56% [12] Business Line Data and Key Metrics Changes - Revenue from Advanced Nodes was $93 million, a 96% increase over Q4, representing 35% of total revenue [11] - Specialty Devices and Advanced Packaging revenue decreased by 24% from Q4 to $129 million, accounting for 48% of revenue [12] - Software and Services revenue was $44 million, down 5% compared to Q4, representing 17% of revenue [12] Market Data and Key Metrics Changes - The Advanced Nodes market showed significant growth, driven by increased investments in AI compute engines and cloud servers [4] - Specialty device and advanced packaging markets experienced a decline, but long-term outlooks for AI packaging are improving [7][16] Company Strategy and Development Direction - The company is accelerating strategic programs to improve business continuity by establishing manufacturing capabilities in Asia, with shipments expected to begin in the second half of 2025 [5] - Onto Innovation is focusing on new product innovations in 2D inspection, 3D metrology, and optical metrology to support advancements in AI and cloud applications [18] Management's Comments on Operating Environment and Future Outlook - Management anticipates a moderate decline in revenue from advanced node customers in Q2 due to timing of investments, but expects growth to resume in Q4 [15][17] - The company is preparing for potential impacts from tariffs but currently does not foresee significant effects on shipments [30] Other Important Information - The company ended Q1 with cash and short-term investments of $851 million, with inventory levels expected to remain flat in Q2 [12][13] - The effective tax rate for the full year is expected to be between 14% to 16% [14] Q&A Session Summary Question: Impact of high bandwidth memory digestion - Management noted no significant changes in the HBM market, with continued investments and product adoptions ongoing [21][23] Question: Guidance for advanced packaging and specialty devices - Management indicated that advanced packaging is facing tough comparisons and tool allocation issues, leading to short-term degradation [25][26] Question: Impact of reciprocal tariffs - Management stated that there has been no current impact from reciprocal tariffs, with exceptions made for semiconductor equipment by China [29][30] Question: Performance of the new 2.5D tool - Management expressed confidence in the new tool's performance, which has been developed to meet evolving customer requirements [35][37] Question: Clarification on Q3 revenue expectations - Management clarified that Q3 is expected to be a low point for total revenue, with advanced nodes also anticipated to decline [42][43] Question: Update on lithography and packaging trends - Management reported strong interest in wide field high-resolution optics and panel packaging, with developments still in R&D stages [47][48] Question: 2.5D packaging platform performance - Management confirmed that while existing equipment met specifications, evolving customer requirements necessitated a new platform for better performance [51][52]

Outfront Media (OUT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Stephan Bisson - Vice President, Investor RelationsNick Brien - Interim CEOMatthew Siegel - EVP & CFODaniel Osley - Vice President, Equity ResearchPatrick Sholl - Vice President Conference Call Participants Cameron McVeigh - Analyst Operator Thank you for your patience, everyone. The Outfront Media First Quarter twenty twenty five Earnings Call will begin shortly. Hello, everyone, and welcome to the Outfront Media First ...

Natera (NTRA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Mike Brophy - Chief Financial OfficerSteve Chapman - Chief Executive OfficerSolomon Moshkevich - President of Clinical DiagnosticsAlexey Aleshin - GM of Oncology and ECD & Chief Medical OfficerNoah Kava - Equity Research AssociateColleen Babington - Equity Research AssociatePuneet Souda - Senior MD Conference Call Participants Daniel Brennan - AnalystTejas Savant - Executive Director & Senior Healthcare Equity AnalystRachel Va ...

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $569 million, representing a 30% year-over-year growth, driven by a 29% increase in total Omnipod growth [21][22] - Gross margin improved to 71.9%, up 240 basis points year-over-year, while adjusted operating margin was 16.4% [34][35] - The company raised its gross margin guidance for the full year to approximately 71% despite an estimated 50 basis point impact from tariffs [43][44] Business Line Data and Key Metrics Changes - U.S. Omnipod revenue grew 26%, exceeding guidance, with strong demand for Omnipod five contributing to this growth [26][27] - New customer starts in the U.S. for Type one and Type two diabetes increased, with over 30% of new starts being Type two [20][21] - International revenue grew 36% above guidance, driven by strong demand for Omnipod five and customer base expansion [31][32] Market Data and Key Metrics Changes - The U.S. market saw a significant increase in healthcare providers prescribing Omnipod five, with nearly 25,000 HCPs now writing scripts, up over 20% from the previous year [30][31] - The company launched Omnipod five in Canada and Switzerland, bringing the total number of international market launches to 13 [32][33] - The international market for Type one diabetes is approximately 3.5 million people, with only 20% to 25% penetration, indicating significant growth potential [99] Company Strategy and Development Direction - The company aims to expand its revenue from $2 billion to $4 billion to $6 billion by focusing on Type one and Type two markets and advancing globalization [12][53] - Strategic priorities include advancing innovation, driving growth in U.S. Type one and Type two populations, and expanding internationally [15][40] - The leadership emphasizes the importance of brand activation and direct-to-consumer strategies to enhance engagement and retention [13][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong first quarter performance and a robust pipeline of innovation [48][49] - The leadership transition is seen as timely, with the new CEO bringing a focus on operational excellence and strategic vision [8][10] - The company anticipates continued strong growth in new customer starts and is optimistic about the adoption of Omnipod five in both Type one and Type two markets [40][41] Other Important Information - The company ended the quarter with approximately $1.3 billion in cash and a $500 million credit facility available, enhancing financial flexibility [37][36] - The board authorized a stock repurchase program of up to $125 million to offset dilution from stock-based compensation [46] Q&A Session Summary Question: What excites you about the role at Insulet and your vision for the business? - The new CEO expressed passion for the diabetes space and highlighted the company's strong momentum and unique position in the market [54][56] Question: Will there be a focus on top-line growth at the expense of margin expansion? - The CEO reassured that the business strategy remains intact, with continued focus on both growth and margin improvement [62] Question: What is the status of the Type two pump adoption in the U.S.? - The management reported strong progress in the Type two launch, with over 30% of new customer starts coming from this segment [65] Question: Can you confirm the strong new start growth in both the U.S. and internationally? - Management confirmed significant strength in new customer starts, both sequentially and year-over-year, driven by the differentiation of Omnipod five [74][75] Question: What are the expectations for gross and operating margin expansion in the coming years? - The management expressed confidence in maintaining industry-leading gross margins while continuing to invest in growth opportunities [78][81] Question: How is the direct-to-consumer advertising performing? - The company reported higher conversion rates from direct-to-consumer advertising efforts, indicating effective engagement strategies [109]

Financial Data and Key Metrics Changes - First quarter revenue was $1,040 million, down 1.4% year over year, with constant currency revenue roughly flat [20][19] - Non-GAAP EPS was $0.97, at the upper end of guidance [19][27] - Non-GAAP gross margin increased by 30 basis points year over year to 67.4% [25] - Non-GAAP operating margin was 20.4% in Q1 [27] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $696 million, growing approximately 1% year over year [20] - Sequencing instruments revenue was approximately flat year over year at $109 million [23] - Sequencing service and other revenue was down approximately 5% year over year to $142 million [24] Market Data and Key Metrics Changes - Clinical business showed mid single-digit growth, while research business was down in the high mid to high single-digit range [50][49] - Approximately 68% of high throughput gigabases shipped were on the NovaSeq X Series [22] - Over 50% of clinical volumes are now on the NovaSeq X Series [22] Company Strategy and Development Direction - The company aims for high single-digit revenue growth and 500 basis points margin expansion by 2027, excluding Greater China [10] - A $100 million cost reduction program was initiated to address challenges from China and research funding uncertainty [12] - The company is focusing on advancing the Multiomics ecosystem and has a strong innovation pipeline [9][17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged macroeconomic challenges but expressed confidence in the company's resilience and growth potential [7][10] - The company is revising guidance to reflect headwinds from China and research funding uncertainties [11][29] - Management emphasized that the challenges are transitory and will not define long-term success [10] Other Important Information - The company is engaging with regulatory authorities in China for potential solutions to support a sustainable long-term presence [11] - The impact of new tariffs is estimated to be approximately $85 million for 2025, with actions being taken to mitigate this [35][36] Q&A Session Summary Question: What is the outlook for revenue growth and margin expansion? - Management believes that revenue growth will rebound and margins will expand above 25% in the future, despite current challenges [42] Question: What are the clinical and research revenue growth rates? - Clinical revenue grew mid single digits, while research revenue declined in the high mid to high single-digit range [50][49] Question: How is the company managing risks related to China? - The company has taken actions to offset potential risks from China, including a $100 million cost reduction program [46] Question: How are tariffs impacting demand? - No significant change in customer behavior was observed in Q1 due to tariffs, but future impacts are anticipated [68][70] Question: What are the assumptions behind the revenue guidance? - The guidance reflects a 15% decline in research revenue, offset by stronger clinical performance [76][78]

HubSpot (HUBS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Ryan Burkart - Senior Director - Investor RelationsYamini Rangan - CEOKate Bueker - CFOMark Murphy - MD - Software ResearchDharmesh Shah - Co-Founder & CTOSamad Samana - Managing DirectorArjun Bhatia - Co-Group Head - Technology, Media & CommunicationsJackson Ader - Managing DirectorKirk Materne - Senior Managing Director - Equity Research Conference Call Participants Gabriela Borges - AnalystAlex Zukin - AnalystRishi Jaluria ...

Expedia Group (EXPE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Harshit Vaish - SVP of Corporate Development, Strategy & Investor RelationsAriane Gorin - CEOScott Schenkel - CFOJustin post - Managing DirectorNaved Khan - Managing Director - Equity ResearchJed Kelly - Managing Director - Equity Research Conference Call Participants Deepak Mathivanan - Senior Equity Research AnalystTrevor Young - AnalystEric Sheridan - AnalystConor Cunningham - AnalystLee Horowitz - AnalystNone - Anal ...

Akamai (AKAM) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Mark Stoutenberg - Head of Investor RelationsTom Leighton - Chief Executive OfficerEd McGowan - CFOAmit Daryanani - Senior Managing Director - Equity ResearchJosh Yeager - Software Equity ResearchJohn DiFucci - Senior Managing Director Conference Call Participants Jonathan Ho - Research AnalystWilliam Power - Senior Research AnalystNone - AnalystJeff Van Rhee - Partner & Senior Analyst - Equity ResearchRudy Kessinger - Managin ...

Pinterest (PINS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Andrew Somberg - Vice President, Investor Relations and TreasuryBill Ready - Chief Executive OfficerJulia Donnelly - Chief Financial OfficerEric Sheridan - Managing DirectorBrian Nowak - Managing Director Shweta Khajuria - Managing DirectorRon Josey - Managing DirectorRich Greenfield - General PartnerJustin Patterson - Managing Director Conference Call Participants Ross Sandler - AnalystKen Gawrelski - AnalystJohn Blackledg ...